Icon
+91 94997 68112
Login Register

Rydapt - (25 mg; Capsule, Oral)

Midostaurin Novartis
25 mg; Capsule, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
Less Than 5
 None
RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: • Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutationpositive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation (1.1). Limitations of Use: RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. • Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). (1.2)
Yes
**** ******* **. *****'* *** **** *********. **, **. ***** *** ****** **** ********. ***** ** ******* *********** *** ***** **** ** ******. *** ******-***** **** ** **** **** (**** **. *****'*) ***** ****** ** ******* **** ******** **, ****. *** ********** **** ********** ******** ** *** ******** ******* ******** ******* ** ******* **** ******* **, **** (***** *** ***-**** ***** **** *** *** ******** ** ***** **, ****). *** ** *.*.*. § ***(*)(*)(*)(**).
Rydapt Patent 1 Patent 2 Patent 3
***** ****** ******* ******* *******
***** *** ********* *** ********* *******
** *****'* ******* *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** ****** ***\ ********* *** **, **** ******* ********* ******** ******* *** **** *** *** ****
** *****'* ***\ ********* *** **, **** ******* **** ******* *** **** *** *** ****
***** ***\ ********* *** **, **** ******* ******** ******* *** **** *** *** ****
  1. *** **, **** : ******** **** ** *****'* ** ****** '*** (*** **,****) *** ***** ** ****** '*** (*** *, ****).
  2. *** **, **** : ******** **** ***** *** **** ** ******* '***(*** **, ****), '*** (*** **, ****) *** '*** (*** *, ****).
  3. *** **, **** : ******** ********* **** ******* ** *****'*
  4. *** **, **** : ****** (*****) ******** ******** ***** *** **** ** ****** **** ****** '*** (*** **, ****)
  5. *** *, **** : ******** ******* **** ***** ** ****** ******* ** ******* *****.
  6. *** *, **** : ******** **** ****** (*****) **** ************ ** ****** '*** (*** **, ****)
  7. *** **, **** : ******** ********* ********** ******* ****** (*****). ** ****** ********* ** ** ****** ** ****** (*****)
  8. *** **, **** : ********* ** **'* ******* *********, **** ****** ************ ** ****** '*** *** '***. ******** *** **** **** ******* *********** **** ******* *****.
  9. *** *, **** : ********* ** **'* ******* *********, **** ****** ************ ** ****** '*** *** '***. ******** *** **** **** ******* *********** **** ******* *****.
  10. *** *, **** : ********* ** **'* ******* *********, ***** ****** ************ ** ****** '***. ******** *** **** **** ******* *********** **** ******* *****.
  11. *** **, **** : ********* ** **'* ******* *********, **. ****** ****** ************ ** ****** '***. ******** *** **. ****** **** ******* *********** **** ******* *****.
  12. *** **, **** : ******** *** ***** ****** **** ******* ********** **** ******* *****.
  13. *** **, **** : ******** *** ****** (*****) **** ******* ********** **** ******* *****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.